Wall Street analyst estimates for PharmaCyte Biotech, Inc. (PMCB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Valuation Ratios
| Price / Book | 0.12 |
| EV / EBITDA | 2.52 |
| Dividend Yield | 0.00% |
Price
| Price | $0.42 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BCLI · CYCN · IBO · KTTA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of PMCB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks